Manesh Patel, MD

Duke University School of Medicine

Articles by Manesh Patel, MD

Updating the Hypertension Treatment Landscape With Manesh Patel, MD

September 4th 2025

Patel addresses the updated AHA/ACC hypertension guidelines, explaining important features and highlighting the potential of newer therapies.

Overcoming Access Barriers to Novel Non Statin Therapies

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh Patel, MD,Pam Taub, MD, FACC, FASPC

December 21st 2023

Dr Taub describes effective strategies in overcoming access barriers to novel lipid lowering therapies.

Concluding Thoughts

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 10th 2022

A panel of expert cardiologists share their concluding thoughts on management of polyvascular disease in clinical practice.

Unmet Needs and Emerging Approaches to Management of Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 10th 2022

Cardiologists share unmet needs and emerging approaches to management of patients with polyvascular disease.

VOYAGER Trial and DPI in Clinical Practice

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 10th 2022

Manesh Patel, MD, reviews VOYAGER trial data and expert cardiologists share where they use DPI [dual pathway inhibition] in their practices.

COMPASS Trial for CAD and PAD

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 3rd 2022

Expert cardiologists discuss data from COMPASS trial and the role of rivaroxaban and low-dose aspirin in treatment of patients with CAD and PAD.

Access to and Awareness of DPI for Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 3rd 2022

Sahil Parikh, MD, shares how lack of access to or awareness of DPI [dual pathway inhibition] causes many practices and health care providers to face a challenge in treating CAD [coronary artery disease].

Direct Oral Anticoagulants and Dosing

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 27th 2022

Drs Patel and Bhatt discuss importance of correct dosing of direct oral anticoagulants in treatment of cardiovascular diseases.

Dual Pathway Inhibition in Coronary Artery Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 27th 2022

Expert cardiologists provide an overview of dual pathway inhibition, modulation of thrombotic risk and treatment of CAD.

Risk-Benefit Analysis in Treatment Selection in CAD

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 20th 2022

Dr Amy Pollak shares her thoughts on risk-benefit analysis when evaluating patients with high thrombotic/bleeding risk and treatment selection.

Stents in Treatment of CAD and PAD

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 20th 2022

Dr Eric Secemsky discusses how use of stents has evolved over the years in treatment of polyvascular disease.

Dual Antiplatelet Therapy in CAD

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 13th 2022

Dr Manesh Patel and other experts discuss the role of dual antiplatelet therapy (DAPT) in treatment of coronary artery disease.

Regimen Intensification in Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 13th 2022

Drs Marc Bonaca and Deepak Bhatt discuss the role of therapy intensification when managing high-risk patients with polyvascular disease.

Guidelines and Management of Patients With Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 6th 2022

Expert cardiologists discuss CAD guidelines and approaches to management of patients with polyvascular disease.

Provider Engagement and Screening

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 6th 2022

Dr Sahil Parikh and other experts discuss engagement of cardiologists in patients diagnosed with polyvascular disease and challenges in screening patients.

Screening for Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

April 29th 2022

Dr Amy Pollak and other experts discuss their recommendations for screening for CAD and PAD in asymptomatic patients.

Overview of Polyvascular Disease and Coronary Artery Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

April 29th 2022

Drs Marc Bonaca and Manesh Patel provide an overview of Polyvascular Disease and prevalence of coronary artery disease and peripheral artery disease.

Treatment Decisions and its Relation to Patient Accessibility

ByKeith C. Ferdinand, MD,Linda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD

May 17th 2021

Final thoughts from expert KOLs regarding treatment decisions and how they relate to patient accessibility when manage dyslipidemia.

Shared Decision Making and Value-Based Care

ByKeith C. Ferdinand, MD,Linda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD

May 17th 2021

Importance of shared decision making and value-based care when making treatment decisions for cardiovascular patients.

Bempedoic Acid for Lipid Lowering

ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD

May 10th 2021

Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.

Dietary and Lifestyle Modifications in Lipid Management

ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD

May 10th 2021

Role of dietary and lifestyle modifications as part of lipid management.

Statins as the Standard of Care for Patients With Dyslipidemia

ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD

May 3rd 2021

Dean Karalis, MD, provides expertise on the appropriate use of statins based on primary and secondary prevention.

Cost-Effectiveness of Inclisiran for Treating Hyperlipidemia

ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD

May 3rd 2021

Expert cardiologists express support for the uptake in the use of inclisiran once approved based on the cost-effectiveness.

Challenging Guidelines in a Non-ACS Population

ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD

April 26th 2021

Norman Lepor, MD, FACC, FAHA, FSCAI, challenges the use of ezetimibe before a PCSK9 inhibitor in a population with no acute coronary syndrome.

Inclisiran in the Current Treatment Landscape for Lipid Lowering

ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD

April 26th 2021

Key opinion leaders in cardiology share their perspectives on using inclisiran post FDA approval within the current treatment landscape based on guidelines.

Phase 3 ORION Trials for Inclisiran

ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD

April 19th 2021

Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.